Adagene - ADR opened lower at $2.11, compared with its previous close of $2.13. In the last trading session, the stock traded between $1.91 and $2.28. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Adagene - ADR is now worth
$ 17.24
Resulting in a loss of
$ 82.76 (82.76%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
80%
Hold
20%
Sell
0%
Markets Today
Today's Change
$-0.13 (-6.10%)
Day High
$2.28
Day Low
$1.91
Day Open
$2.11
Prev Close
$2.13
Volume
2,70,612
1W Return
-17.83%
1M Return
-26.82%
3M Return
-48.65%
6M Return
-47.23%
1Y Return
17.65%
Fundamentals
Market Cap ($ Mn)
134
PE Ratio
-
PB Ratio
2.75
PEG Ratio
-
ROE
-42.68%
ROCE
-41.67%
EPS (TTM)
-
Investment Returns
1 Week
-17.83%
1 Month
-26.82%
3 Months
-48.65%
6 Months
-47.23%
9 Months
-35.48%
Financials
Quarterly
All values in $ Mn
0.5
Dec 19
0.0
Sep 20
0.4
Dec 20
Updates
9Nov
Adagene completes enrollment in Phase 2 trial of muzastotug for MSS CRC
Adagene completed patient enrollment in its Phase 2 dose-optimization trial. The study tests muzastotug combined with Merck's KEYTRUDA. Target indication is microsatellite stable colorectal cancer without liver metastases. Muzastotug is a masked anti-CTLA-4 SAFEbody developed by Adagene.
3 days ago
19Oct
HC Wainwright reiterates Buy on Adagene, keeps $7 target
HC Wainwright & Co. reiterated Buy rating on Adagene. Price target maintained at $7 per share. Analyst Arthur He issued the rating update.
24 days ago
10Sep
Third Arc Bio selects lead candidate under Adagene license deal
Third Arc Bio selects first lead candidate under Nov 2025 Adagene deal. Third Arc Bio to sponsor and fund clinical development of the program. Total potential milestone payments to Adagene increased under new terms. Adagene retains no-cost option for Greater China, Singapore, South Korea.
2mo ago
20Aug
Adagene management to present at three September healthcare conferences
Adagene Inc. (NASDAQ: ADAG) will participate in three major healthcare investor conferences in New York during September 2026. The engagements include one-on-one meetings and fireside chats at Cantor Fitzgerald, Morgan Stanley, and H.C. Wainwright events. Webcasts will be available on the company's investor site for 30 days post-conference.
2mo ago
12Aug
Adagene H1FY26 net loss widens to $16.4M; misses quarterly EPS estimate
Adagene Inc. reported a widened H1FY26 net loss of $16.4 million, with quarterly EPS of $(0.20) missing estimates of $(0.10). Revenue reached $1.6 million from collaboration milestones. Cash reserves increased to $127.9 million following an April offering, supporting development of lead candidate muzastotug through late 2028.
